Hansa Biopharma — Oktober 2024
-
Søren Tulstrup, President and CEO, Hansa Biopharma said, “There is mounting clinical evidence that faster and more robust IgG reduction is directly linked to more successful therapeutic outcomes in autoimmune and other diseases. We are very encouraged by these results that demonstrate HNSA-5487 can robustly and very rapidly reduce IgG levels, has redosing potential, and a favorable safety and tolerability profile. ...
-
... We believe HNSA-5487 has a highly differentiated profile compared to published data from studies with other IgG-targeted therapies. These results underscore the transformational potential of HNSA-5487 to address significant unmet need across a spectrum of IgG driven diseases and conditions, including autoimmune where there is a clear need for better management of initial and repeat immune system attacks.”
-
Hansa Biopharma Pipeline: https://www.hansabiopharma.com/our-science/pipeline
-
Hansa Biopharma will host a telephone conference on 7 October at 14:00 CET / 8:00 AM EST.
Slides used in the presentation will be available online following the call.
Join the webcast here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6iGh9S4f
-
Hansa Biopharma: NiceR is in a good position to expand the future market
-
Hansa's next-gen IgG degrader shows promise, sparks stock rally https://firstwordpharma.com/story/5901548
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind